High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy
Xiangyu Sun, Xiao-Ting Cai, Shangbiao Li, Ruozheng Pi, Ze-Qin Guo, Jiayu Jiang, Pinhao Wang, Jingrong Xiong, Zhuangzhuang Liu, Zixuan Rong, Zihang Yu, Xiaonan Zhang, Jiaqi Chen, Duan-Duan Han, Yan-Pei Zhang, Jia-Le Tan, Yan Lin, Zhuocheng Zou, Hanxu Ai, Fangfang Kang, Xue‐Jun Guo, Zhong‐Yi Dong, Dehua Wu, Xue Bai
Abstract
DC populations, both Tpex expansion and therapeutic benefits are abrogated, confirming DC dependence. In addition, GSDME is validated as a gatekeeper of pyroptosis-driven antitumor immunity. This work provides a rationale for clinical trials combining ICI with high-dose AA.
Topics & Concepts
PyroptosisCancer researchCD8Ascorbic acidProgrammed cell deathT cellImmune systemCytotoxic T cellImmunogenic cell deathApoptosisChemistryImmunotherapyBiologyCell biologyImmunologyBiochemistryIn vitroFood scienceVitamin C and Antioxidants ResearchInflammasome and immune disordersCell death mechanisms and regulation